Opendata, web and dolomites

OvaVAx SIGNED

100% Bacteria free eggs for use in production of human and animal vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OvaVAx project word cloud

Explore the words cloud of the OvaVAx project. It provides you a very rough idea of what is the project "OvaVAx" about.

seven    specialises    providers    2021    external    whilst    world    yield    pharmaceutical    founders    health    investors    worth    eliminate    pull    pathogen    superior    utilising    egg    quality    rapid    group    demand    chicken    innovative    annually    germ    manufacture    industries    vaccine    free    lives    eggs    protect    demands    2022    global    ceo    coo    first    led    bacterial    12    good    manufacturers    benefits    supplier    ltd    exceptionally    services    opportunity    ogl    spf    transgenics    globally    contamination    usd    vaccines    viral    patent    89bn    company    immunisation    leonard    yields    biopharma    catherine    invested    commercially    agr    populations    skills    caulfield    ovagen    market    industry    fertilised    innovation    protected    servicing    vision    considerable    enterprise    disruptive    serial    contract    avian    ireland    biotechnology    service    cagr    gf    48bn    1bn    dr    entrepreneurs    moran    size    specialist    team    pandemic    manufacturing    91m    standards          vc    expertise   

Project "OvaVAx" data sheet

The following table provides information about the project.

Coordinator
OVAGEN GROUP LIMITED 

Organization address
address: CARRENTRILA
city: BALLINA
postcode: F26PC79
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙366˙875 €
 EC max contribution 2˙356˙812 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OVAGEN GROUP LIMITED IE (BALLINA) coordinator 2˙356˙812.00

Map

 Project objective

Disruptive technology for improved quality and viral yield in egg-based vaccine production and other biotechnology applications. Ovagen Group Ltd. (OGL) is an innovation-based biotechnology company, led by serial entrepreneurs, providing specialist contract services to Biopharma, Pharmaceutical and Vaccine industries. OGL specialises in avian Germ-Free (GF) technology and avian transgenics to Good Manufacturing Practice standards. The company’s vision is to be the go-to supplier of superior quality GF eggs to the vaccine industry globally by 2021.

INNOVATION: The founders Dr Leonard Moran CEO and Dr Catherine Caulfield COO together with external VC investors and Enterprise Ireland have invested €12.91M in seven years of R&D, utilising the considerable skills, expertise and experience of our team within this field to develop a unique and novel, patent protected process to enable commercially viable production of the World’s first germ-free (GF) eggs, to eliminate bacterial contamination through eggs for vaccine development and production. This will result in improved quality, production costs and viral yields for vaccine manufacturers leading to cost and availability benefits for health service providers for immunisation programmes to protect the health and lives of populations whilst enabling a rapid response to Global pandemic demands. There is exceptionally strong market pull for our innovative disruptive technology, and the increasing use of vaccines to support global demand for quality eggs estimated CAGR of 8.8% and market value of USD 1.89Bn by 2022.

OPPORTUNITY: Over 1bn fertilised specific pathogen free (SPF) chicken eggs are used annually in vaccine manufacture, servicing a vaccine market size estimated to be worth €48bn by 2021 with an AGR of 8.3%.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OVAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OVAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More